Entries by

The Forgotten Ones. Will Long-haulers Be The Next Public Health Crisis? A Live Online Discussion On Covid-19 Long-haulers

Miami Beach, Florida — January 12th, 2021 — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) (the “Company” or “Organicell”), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, will host a live online discussion on the topic of COVID-19 long-haulers on Wednesday, January 13th at 7 P.M. EST. As noted by many experts in the field, […]

Organicell™ Regenerative Medicine and Its Investigational Therapeutic Zofin™ Featured in Two National Publications Examining Potential Therapies for Covid-19 Long-haulers

Miami Beach, Florida — December 29, 2020 — Organicell Regenerative Medicine, Inc. (OTCMKTS:BPSR) (the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies today announced that the Company and its therapeutic drug Zofin™ were recently featured in articles in both the Wall Street Journal and BioSpace, which examined potential therapies for COVID-19 […]

Organicell™ Regenerative Medicine, Inc. Becomes Current With SEC Reporting Requirements

Miami, FL (December 22, 2020) — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR) (the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it is now current in its SEC reporting requirements under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) Upon filing its Quarterly Report on Form 10-Q for […]

Organicell Announces Additional Site for Phase I/II Clinical Trial of ZofinTM for Treatment of COVID-19

Miami, FL (November 18, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it is now enrolling patients at an additional site, Larkin Hospital North located in Hialeah, Florida for its Phase I/II clinical trial for the use of its Zofin™ therapeutic […]

Organicell Provides Update on Its COVID-19 Clinical Trial Using ZofinTM

Anticipates Phase I/II trial completion by end of year Anticipates Phase IIb trial to begin in Q1 2021 Seeks to retain a global contract research organization (“CRO”) Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today provided an update on its Phase I/II clinical trial for […]

Organicell Partners with Regenerative Care Network to Study Potential Therapeutic Benefits of Zofin™ for Patients with Heart Failure

MIAMI, Oct. 20, 2020 (GLOBE NEWSWIRE) — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it has recently entered into an agreement with Regenerative Care Network (“RCN”). Organicell and RCN plan to collaborate on clinical research projects investigating use of Organicell’s lead therapeutic, Zofin™, […]